Liquidia (NASDAQ:LQDA) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital assumed coverage on shares of Liquidia (NASDAQ:LQDA) in a report published on Thursday morning, Benzinga reports. The firm issued an outperform rating and a $30.00 target price on the stock.

A number of other brokerages have also weighed in on LQDA. Needham & Company LLC reiterated a buy rating and issued a $25.00 price objective on shares of Liquidia in a research report on Monday, August 19th. BTIG Research cut their target price on shares of Liquidia from $29.00 to $25.00 and set a buy rating on the stock in a research note on Monday, August 19th. Oppenheimer started coverage on shares of Liquidia in a research report on Tuesday, June 25th. They set a market perform rating on the stock. HC Wainwright lowered their price objective on shares of Liquidia from $32.00 to $29.00 and set a buy rating for the company in a report on Tuesday, August 20th. Finally, Raymond James upgraded Liquidia from an outperform rating to a strong-buy rating in a report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $24.00.

Liquidia Stock Performance

NASDAQ LQDA opened at $10.03 on Thursday. The company has a fifty day moving average of $10.44 and a 200-day moving average of $12.22. Liquidia has a 52-week low of $5.71 and a 52-week high of $16.99. The company has a market capitalization of $766.43 million, a P/E ratio of -6.43 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $3.66 million for the quarter, compared to the consensus estimate of $7.92 million. Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. As a group, analysts forecast that Liquidia will post -1.71 EPS for the current fiscal year.

Insider Activity

In related news, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the sale, the chief financial officer now owns 312,389 shares in the company, valued at $3,914,234.17. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Caligan Partners Lp bought 150,000 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was acquired at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the acquisition, the director now owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the transaction, the chief financial officer now owns 312,389 shares in the company, valued at approximately $3,914,234.17. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,422 shares of company stock worth $256,998. Insiders own 31.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently added to or reduced their stakes in LQDA. Quest Partners LLC bought a new stake in shares of Liquidia in the 2nd quarter worth $27,000. Hilltop National Bank purchased a new stake in shares of Liquidia during the second quarter valued at $33,000. Whitcomb & Hess Inc. increased its holdings in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after buying an additional 1,074 shares in the last quarter. Deuterium Capital Management LLC bought a new stake in Liquidia in the 2nd quarter worth about $120,000. Finally, DMC Group LLC purchased a new position in Liquidia in the 2nd quarter worth about $122,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).